RESEARCH TRIANGLE PARK, N.C., Oct. 17, 2011 /PRNewswire/ -- Max Neeman International is the only CRO in India to manage hemophilia trials according to the Clinical Trials Registry-India (CTRI). Of the total hemophilia trials currently being conducted in India, Max Neeman can boast supporting 80% of these with the remaining conducted by pharma companies. Max Neeman International has established a team of experts specialized in carrying out hemophilia trials in response to sponsor demand. The team has the required expertise via involvement of academia with industry, hemophilia trial experience and extensive database of best Investigators for indication to develop innovative approaches to optimize complex study design. Often strict inclusion/exclusion criteria and data analysis for such studies create the greatest challenge for Biotech and Pharma that the company's expertise can address.
(Logo: http://photos.prnewswire.com/prnh/20110105/CL25129LOGO )
Max Neeman is a leading CRO in India that has a focus on hemophilia and bleeding disorder studies, in addition to other indications. Patient enrollment for complex global and multi-centric hemophilia trials is challenging because potential subjects are fewer in number and widely dispersed. With an Incidence of 1 in 10,000 people, India has more than 120,000 hemophilic and thus it has evolved into a preferred destination for conducting such trials because of low cost and faster patient recruitment.
About Max Neeman International
Max Neeman International is one of the leading and largest CROs in India. Our specialty is that we offer services for the successful conduct of Phase II-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 & ISO 27001:2005 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in 31 cities with 6 regional offices. For more information, please contact Donald Swankie, Vice President of Business Development at +1.919.424.3345 / email@example.com or visit www.neeman-medical.com.
SOURCE Max Neeman International